ClinicalTrials.gg
CompletedNCT02180412Updated Apr 11, 2025Results posted

Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria

A Phase 2 interventional study of Panhematin and Glucose in Acute Porphyrias, sponsored by The University of Texas Medical Branch, Galveston. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by The University of Texas Medical Branch, Galveston · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.

Started
2014
with 1 other
Phase 2
2 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
3 of 12
The University of Texas Medical Branch, Galveston

Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is one of 2 that started in 2014, is one of 2 in phase 2, and was the 4th registered.

Porphyria, Acute Intermittent

21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.

Browse Porphyria, Acute Intermittent studies →

Open to participants now

2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Porphyria, Acute Intermittent with a site in United States, or all of them as a file.
02

Study summary

This study aims to provide high quality evidence for the effectiveness and safety of hemin (PanhematinTM , Recordati) for treatment of acute attacks of porphyria. These types of studies have not been done before with either PanhematinTM or the hemin preparation available in Europe (NormosangTM, Orphan Europe).

There are two treatment groups in this study. One group will be treated with PanhematinTM plus glucose, and the other group will be treated with glucose plus an inactive salt solution (called a "placebo"). To avoid prejudice, the treatment given to each participant will be blinded (meaning the participants and most of the hospital staff will not know which treatment the participant will receive) and randomized (meaning participants will have an equal chance of receiving either treatment, like the flip of a coin). A placebo-controlled, randomized study is the standard method used to prove treatments are effective and safe. PanhematinTM and glucose will be given in the same manner as is usual for treating an attack of porphyria. For participants who are chosen to receive the placebo, their treatment will be switched to real PanhematinTM at any time if their symptoms do not improve. This is called "rescue" treatment, and assures that they study is safe and patients who need hemin will receive it. Treatment with hemin will be for 4 days, or longer if needed. Since the study treatment is started as soon as possible after symptoms appear, there will be very little delay in providing hemin to those who need it. Funding Source - Office of Orphan Products Development (FDA OOPD)

03

Conditions studied

  • Acute Porphyrias

Keywords

  • Acute porphyria
  • Hemin
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 years
  • Willing to provide written
  • Acute symptoms (7 days duration or less to time of enrollment) such as abdominal, back and/or limb pain, diagnosed by the investigator as caused by porphyria after initial evaluation has excluded other causes.
  • Diagnosis of acute porphyria documented by a substantial increase in urinary or serum porphobilinogen (PBG).
  • Type of acute porphyria confirmed by additional testing (in addition to increased PBG), which may be completed before or after treatment begins using pretreatment samples:
  • For acute intermittent porphyria (AIP): Normal or only slight increases in plasma and fecal porphyrins. Most (\~90 percent) will have deficient activity of erythrocyte porphobilinogen deaminase (PBGD), and almost all (>95 percent) will have a demonstrable disease-causing PBGD mutation.
  • For hereditary coproporphyria (HCP): Substantial increases in fecal porphyrins (almost entirely coproporphyrin III). In the absence of skin photosensitivity, most will have normal or only slight increases in plasma porphyrins. Almost all (>95 percent) will have a demonstrable disease-causing coproporphyrinogen oxidase (CPO) mutation.
  • For variegate porphyria (VP): Substantial increases in fecal porphyrins (mostly coproporphyrin III and protoporphyrin), increased plasma total porphyrins and a fluorescence emission maximum of diluted plasma at neutral pH near 626 nm. Almost all (\~95 percent) will have a demonstrable disease-causing protoporphyrinogen oxidase (PPO) mutation.

Exclusion criteria

Exclusion Criteria:

  • Symptoms such as abdominal, back or limb pain are explained by another condition, as judged by the investigator
  • Therapy with hemin within 7 days prior to enrollment in this study
  • Known or suspected allergy to Panhematin™ or related products
  • Preexisting coagulation defect or concurrent treatment with an anticoagulant
  • Previously documented renal impairment defined as a serum creatinine above 1.7 mg/dL or 150 mmol/L.
  • A diagnosis of diabetes mellitus, which might increase the risk of glucose infusion.
  • Heart failure, significant chronic anemia or any disease or condition that the investigator judges would lead to an unacceptable risk to the patient or interfere with the successful collection of date for the trial
  • Previous randomization in this trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Panhematin

    Panhematin plus glucose

    Biological: Panhematin · Other: Glucose

  • Placebo comparator
    Placebo

    Placebo (saline) plus glucose

    Other: Glucose

Interventions

  • BiologicalHeminStudies of HeminHemin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Glucose loading

    Also known as: Glucose

  • OtherGlucose

    Glucose is administered to both groups as routine care.

06

What researchers measure

Primary outcomes

  1. Difference in NRS Pain Score Between Baseline and 12 Hours

    The difference in the pre-infusion NRS pain scores and NRS pain score 12 hours from the infusion start time. To define this variable, all blinded study treatment infusion times were compared with the pain score survey times. The pain score closest to but prior to the infusion time was the pre-infusion pain score. Numeric rating scale for pain (0-10; 0=no pain, 10=most severe pain).

    Time frame: Baseline and 12 hours

Secondary outcomes

  1. Biochemical Effects of Panhematin In Participants Treated Early For Attacks of Porphyria

    Difference in the panhematin and placebo arm for the change in urinary ALA, (PBG), and total porphyrins between baseline and subsequent time points.

    Time frame: Day 1 (baseline), Day 2, Day 3 and Day 4

Other outcomes

  1. Effects of Clinical Features on Response to Panhematin

    Age, sex, exacerbating factors

    Time frame: 4 days

  2. Effects of Genetic Features on Response to Panhematin

    Types of mutations

    Time frame: 4 days

  3. Use of Reconstitution of Panhematin With Albumin

    Frequency of side effects or adverse events

    Time frame: 4 days

07

Results

Posted Apr 3, 2025

Participant flow

Participant flow — Overall Study
MilestonePanhematinPlacebo
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryDifference in NRS Pain Score Between Baseline and 12 Hours

The difference in the pre-infusion NRS pain scores and NRS pain score 12 hours from the infusion start time. To define this variable, all blinded study treatment infusion times were compared with the pain score survey times. The pain score closest to but prior to the infusion time was the pre-infusion pain score. Numeric rating scale for pain (0-10; 0=no pain, 10=most severe pain).

Time frame:
Baseline and 12 hours
Reported as:
Mean · score on a scale
Difference in NRS Pain Score Between Baseline and 12 Hours
score on a scalePanhematinPlacebo
Difference in NRS Pain Score Between Baseline and 12 Hours-0.2 ± 2.2-0.2 ± 1.9
SecondaryBiochemical Effects of Panhematin In Participants Treated Early For Attacks of Porphyria

Difference in the panhematin and placebo arm for the change in urinary ALA, (PBG), and total porphyrins between baseline and subsequent time points.

Time frame:
Day 1 (baseline), Day 2, Day 3 and Day 4
Reported as:
Mean · mean difference of mg/g creatinine
Biochemical Effects of Panhematin In Participants Treated Early For Attacks of Porphyria
mean difference of mg/g creatininePanhematinPlacebo
ALA Day 1 vs Day 28.47 ± 8.972.31 ± 5.5
ALA Day 1 vs Day 313.27 ± 11.45-0.57 ± 6.01
ALA Day 1 vs Day 414.90 ± 11.851.99 ± 10.73
PBG Day 1 vs Day 26.56 ± 11.69-2.94 ± 12.85
PBG Day 1 vs Day 315.56 ± 17.88-7.08 ± 10.76
PBG Day 1 vs Day 420.16 ± 18.63-5.83 ± 20.00
Total Porphyrins Day 1 vs Day 2297.60 ± 948.90317.00 ± 682.93
Total Porphyrins Day 1 vs Day 3594.00 ± 1173.48165.00 ± 678.41
Total Porphyrins Day 1 vs Day 4606.11 ± 1238.87331.33 ± 836.59
Statistical analysis
  • Panhematin vs Placebo · ANCOVA · p = .0434 · Slope: 7.76 · 95% CI 2.14 to 13.37
  • Panhematin vs Placebo · ANCOVA · p = .0003 · Slope: 16.29 · 95% CI 11.32 to 21.25
  • Panhematin vs Placebo · ANCOVA · p = .0198 · Slope: 15.98 · 95% CI 6.7 to 25.26
  • Panhematin vs Placebo · ANCOVA · p = .158 · Slope: 10.69 · 95% CI -1.67 to 22.49
  • Panhematin vs Placebo · ANCOVA · p = .0127 · Slope: 24.52 · 95% CI 11.3 to 37.74
  • Panhematin vs Placebo · ANCOVA · p = .0328 · Slope: 28.45 · 95% CI 9.64 to 47.27
  • Panhematin vs Placebo · ANCOVA · p = .9993 · Slope: 12.2 · 95% CI -465.4 to 489.8
  • Panhematin vs Placebo · ANCOVA · p = .2915 · Slope: 454.5 · 95% CI -200.87 to 1109.86
  • Panhematin vs Placebo · ANCOVA · p = .4382 · Slope: 326.12 · 95% CI -292 to 944.25
Other pre-specifiedEffects of Clinical Features on Response to Panhematin

Age, sex, exacerbating factors

Time frame:
4 days

Results for this outcome have not been posted.

Other pre-specifiedEffects of Genetic Features on Response to Panhematin

Types of mutations

Time frame:
4 days

Results for this outcome have not been posted.

Other pre-specifiedUse of Reconstitution of Panhematin With Albumin

Frequency of side effects or adverse events

Time frame:
4 days

Results for this outcome have not been posted.

Adverse events

Collected over Day 1 (baseline), Day 2, Day 3 and Day 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panhematin0/10 (0%)0/10 (0%)0/10 (0%)
Placebo0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)PanhematinPlaceboTotal
Mean36.6 ± 6.236.7 ± 11.236.7 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)PanhematinPlaceboTotal
Female101020
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PanhematinPlaceboTotal
Hispanic011
Non-Hispanic American Indian or Alaskan native101
Non-Hispanic Asian011
Non-Hispanic Black or African American022
Non-Hispanic White9615
08

Study locations

1 site
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Feb 2022, 93 months.

Results were first posted in Apr 2025, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jul 2, 2014
StartActual
Apr 28, 2014
Primary completionActual
Feb 3, 2022
CompletionActual
Feb 3, 2022
Results first posted
Apr 3, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02180412
Responsible party
Sponsor
First posted
Jul 2, 2014
Start date
Apr 28, 2014
Primary completion
Feb 3, 2022
Completion
Feb 3, 2022
Results posted
Apr 3, 2025
Last update
Apr 11, 2025

Study contacts

Karl E Anderson, MD
principal investigator · UT, Galveston

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemin

Start the discussion